Need for awareness and immunization against Respiratory Syncytial Virus in India
RSV, often mistaken for a mild seasonal cold, accounts for ~ 3.6 million hospitalizations and ~ 100,000 deaths in children under five each year globally. India, with the largest birth cohort of ~ 25 million newborns annually, contributes significantly to this burden. The impact is particularly severe during the country's monsoon and early winter months, when neonatal ICUs experience a surge in admissions. Alarmingly, even healthy, full-term infants across all socio-economic backgrounds often require oxygen or ventilator support due to RSV-related complications. Therefore, raising awareness among parents and healthcare professionals about available preventive measures is critical to reducing the disease's toll on young lives.
Dr. Vasant M. Khalatkar, Current National President, Indian Academy of Pediatrics (IAP), said 'RSV remains a significant threat to infant health, and while hygiene measures like handwashing are essential, they're often not enough—especially for babies under one year. With the recent World Health Organization (WHO) recommendation for long-acting monoclonal antibodies (mAb) and India enabling access to these solutions, we now have vital tools to protect our youngest.
Palivizumab has been available for high-risk infants, offering protection through monthly dosing during the RSV season. Now, with the arrival of Nirsevimab—a single-dose, long-acting antibody that provides season-long protection—we're seeing a major advancement. Administered shortly after birth or during routine follow-ups, these preventive options can greatly reduce RSV-related hospitalizations and shield infants from serious complications like bronchiolitis and pneumonia. Prevention, timely awareness, and parental engagement are critical to reducing RSV's impact across India.'
Dr. Cesar Mascarenas, Head of Medical International Region, Sanofi, commented 'We have long been working to close critical gaps in prevention by advancing science-driven solutions that align with evolving global recommendations, including those from the WHO. Addressing RSV burden in India with advanced preventive care is the need of the hour. Strengthening awareness, improving access to protective interventions, and enabling timely immunization are essential steps in reducing the impact of RSV and safeguarding the health of future generations.'
Dr. Bhavesh Kotak, Head, Medical Affairs, Dr. Reddy's, added 'India bears a significant share of the global RSV burden. Unlike high-income countries with advanced prevention care and early access to preventive solution, India still faces challenges in timely diagnosis and protection. Increased awareness around the severity of RSV and enabled access to ground-breaking immunization solutions will be critical in building a more equitable and effective national response to RSV.'
In April 2025, Sanofi and Dr. Reddy's announced the expansion of their partnership to bring to India a novel, single-dose preventive immunization developed to protect infants from RSV-related complications. Caregivers or parents are advised to speak with their pediatricians / neonatologist for more details.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
WHO updates recommendations on use of antibiotics for Covid-19 patients
The WHO has recommended against the use of antibiotics even in patients with severe Covid when a concurrent bacterial infection is not suspected. The global health body has released updated recommendations for the clinical management of people with Covid which, it said, are based on evidence generated from recent meta-analysis of outcomes of patients treated with antibiotics for Covid. "For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics. For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics," the WHO said. The WHO said that as COVID-19 epidemiology and severity have changed, and as emergency measures have subsided, the evidence behind a number of recommendations has changed. In parallel, evolution of health systems and the global environment have meant that the recommendations are implemented in a very different context in 2024 compared to 2020. These guidelines have evolved from the first version in 2020 in line with new information and changing circumstances of the pandemic, the WHO said. "Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity. Emergency measures which were imposed have also been removed, and care for patients with COVID-19 has become more integrated with usual healthcare systems. "This different environment has prompted a review of the scope and content of all existing guidance. In order to maintain a clear focus and relevance, we have removed recommendations which would be considered general medical principles, and those which are no longer specific to the management of COVID-19," the WHO said. The new recommendations on use of antibiotics were prompted by the publication of data from a systematic review and meta-analysis, and the pressing need to address antimicrobial resistance. The WHO said that the updated guidelines are for people directly or indirectly involved in the health care of patients with COVID-19 and post COVID-19 condition. This includes clinicians, allied health care workers, facility managers and hospital administrators. The SARS-CoV-2 continues to infect several thousands of people daily leading to preventable morbidity and mortality across the world, the WHO said. The roll-out of vaccines and treatment for COVID-19, and increasing population immunity from infection has substantially reduced hospitalization, severity of disease, and mortality. "However, the virus continues to evolve in terms of infectivity, immune escape, and disease severity. This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19," the WHO stated. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
News18
6 hours ago
- News18
WHO updates recommendations on use of antibiotics for COVID-19 patients
New Delhi, Aug 6 (PTI) The WHO has recommended against the use of antibiotics even in patients with severe Covid when a concurrent bacterial infection is not suspected. The global health body has released updated recommendations for the clinical management of people with Covid which, it said, are based on evidence generated from recent meta-analysis of outcomes of patients treated with antibiotics for Covid. 'For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics. For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics," the WHO said. The WHO said that as COVID-19 epidemiology and severity have changed, and as emergency measures have subsided, the evidence behind a number of recommendations has changed. In parallel, evolution of health systems and the global environment have meant that the recommendations are implemented in a very different context in 2024 compared to 2020. These guidelines have evolved from the first version in 2020 in line with new information and changing circumstances of the pandemic, the WHO said. 'Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity. Emergency measures which were imposed have also been removed, and care for patients with COVID-19 has become more integrated with usual healthcare systems. 'This different environment has prompted a review of the scope and content of all existing guidance. In order to maintain a clear focus and relevance, we have removed recommendations which would be considered general medical principles, and those which are no longer specific to the management of COVID-19," the WHO said. The new recommendations on use of antibiotics were prompted by the publication of data from a systematic review and meta-analysis, and the pressing need to address antimicrobial resistance. The WHO said that the updated guidelines are for people directly or indirectly involved in the health care of patients with COVID-19 and post COVID-19 condition. This includes clinicians, allied health care workers, facility managers and hospital administrators. The SARS-CoV-2 continues to infect several thousands of people daily leading to preventable morbidity and mortality across the world, the WHO said. The roll-out of vaccines and treatment for COVID-19, and increasing population immunity from infection has substantially reduced hospitalization, severity of disease, and mortality. 'However, the virus continues to evolve in terms of infectivity, immune escape, and disease severity. This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19," the WHO stated. PTI PLB ZMN view comments First Published: August 06, 2025, 22:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
7 hours ago
- News18
Need For A Comprehensive International Health Law Post-Covid: In Light Of New WHO Pandemic Treaty
While health has historically been viewed as a domestic responsibility, Covid-19 reinforced the fact that infectious diseases transcend borders The Covid-19 pandemic manifested the urgent need to strengthen international health law. Historically, health governance has largely been considered a national matter, regulated primarily through municipal laws. Although the World Health Organization (WHO) is one of the oldest international institutions within international law, the over-reliance on national legal frameworks has hindered the development of a comprehensive international treaty on health law. At present, international health governance relies primarily on soft international law, i.e., non-binding instruments such as guidelines, recommendations, and best practices for member states. However, the Covid-19 pandemic exposed gaps in global preparedness and response mechanisms, necessitating the need for a binding international treaty to coordinate pandemic prevention, preparedness, and equitable response across nations. The International Health Regulations (IHR) 2005, though adopted by 196 countries, proved insufficient to manage a crisis of this scale. The IHR 2005 replaced the older IHR 1969, which had focused mainly on controlling specific diseases such as cholera, plague, and yellow fever. It was adopted under Article 21 of the WHO Constitution; however, the 2005 regulations expanded their scope but still relied on state compliance without strong enforcement mechanisms. The pandemic also reinvigorated the debate surrounding whether public health should be treated as part of the global commons. Historically, international law identifies areas such as the high seas, outer space, Antarctica, and the deep seabed as global commons, which are resources beyond national jurisdiction and accessible for the collective benefit of humankind. While health has historically been viewed as a domestic responsibility, Covid-19 reinforced the fact that infectious diseases transcend borders, affecting the entire international community. This would impose collective obligations on states to share resources, technology, and data, particularly in pandemic situations. It would also require a shift from national interest-based approaches to collective international cooperation, ensuring equitable access to vaccines, medicines, and diagnostics. The proposed WHO Pandemic Agreement partially reflects this approach by emphasising pandemic prevention, preparedness, and equitable response. India's Vaccine Maitri: A Case of Health Diplomacy India's Vaccine Maitri (Vaccine Friendship) initiative put into practice the global commons approach in practice. Launched in January 2021, the program aimed at supplying Covid-19 vaccines to low- and middle-income countries, reflecting India's commitment to 'Vasudhaiva Kutumbakam" (the world is one family). India exported millions of doses of vaccines to over 90 countries, including those in Africa, Asia, Latin America, and the Caribbean. This initiative was not only a form of health diplomacy but also an effort to implement the principle of equity in global health governance. By prioritising vaccine access for developing countries, India contributed to global solidarity and demonstrated how states can play a rule-shaping role in international health law, even in the absence of a binding treaty. Vaccine Maitri can serve as an example for future obligations under the proposed Pandemic Agreement, especially regarding technology transfer, intellectual property waivers, and equitable distribution of medical resources. Towards a WHO Pandemic Agreement Recognising the devastating loss of life, economic disruptions, and setbacks to global development caused by Covid-19, WHO Member States emphasised the need for permanent global action to prevent similar crises in the future. The objective of the new treaty, often referred to as the WHO Pandemic Agreement, is to ensure that communities, governments, and all sectors of society are better prepared, protected, and able to respond equitably to future pandemics. To negotiate this treaty, WHO Member States established the Intergovernmental Negotiating Body (INB), which held its first meeting on February 24, 2022. The INB process has since involved 13 formal rounds of meetings, alongside multiple formal and informal consultations to discuss complex provisions of the treaty for securing the future. The INB submitted its first outcome at the Seventy-seventh World Health Assembly in May 2024. The final draft has been submitted for consideration at the Seventy-eighth World Health Assembly in May 2025. The draft addresses gaps and inequities exposed by the Covid-19 pandemic, focusing on equitable access to health products, coordinated funding, and strengthened prevention and response mechanisms. Abhinav Mehrotra and Dr Biswanath Gupta are Associate Professors at OP Jindal Global University. Views expressed in the above piece are personal and solely those of the authors. They do not necessarily reflect News18's views. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
